» Articles » PMID: 36643788

The Policy Landscape for Naloxone Distribution in Four States Highly Impacted by Fatal Opioid Overdoses

Abstract

Background: Expanding access to naloxone is one of the most impactful interventions in decreasing opioid-related mortality. However, state distribution rates of naloxone are insufficient to meet community need. The current study sought to better understand this gap by focusing on state policies that may facilitate or impede naloxone distribution in four states highly impacted by fatal opioid overdoses - Kentucky, Massachusetts, New York, and Ohio.

Methods: We provide a descriptive analysis of the policy landscape impacting naloxone distribution through pharmacy and community channels in the four states participating in the HEALing Communities Study (HCS). Publicly available data and the expertise of the research team were used to describe each state's naloxone access laws (NALs), Medicaid coverage of naloxone, and community overdose education and naloxone distribution infrastructure. Data presented in this study represent the most current policy landscape through September 2022.

Results: Variation exists between specific components of the NALs of each state, the structure of Medicaid coverage of naloxone, and the community distribution infrastructure networks. Massachusetts and New York have a statewide standing order, but other states use different strategies short of a statewide standing order to expand access to naloxone. Quantity limits specific to naloxone may limit access to Medicaid beneficiaries in some states.

Conclusion: States participating in the HCS have developed innovative but different mechanisms to ensure naloxone access. Policies were dynamic and moved towards greater access. Research should consider the policy landscape in the implementation and sustainability of interventions as well as the analysis of outcomes.

Citing Articles

Naloxone Knowledge, Carrying, Purchase, and Use.

Jacobson M, Powell D JAMA Netw Open. 2025; 8(3):e2462698.

PMID: 40029657 PMC: 11877168. DOI: 10.1001/jamanetworkopen.2024.62698.


Intranasal overdose reversal formulations: a rapid review of available agents.

Bernosky-Smith K, Painter O, Butler S, Patel D, Clemency B, Lynch J Pain Manag. 2025; 15(2):105-113.

PMID: 39902734 PMC: 11853544. DOI: 10.1080/17581869.2025.2461445.


Development of a brief stigma and perceptions questionnaire for pharmacists: An exploratory factor analysis approach in New York state counties enrolled in the healing communities study.

Goddard-Eckrich D, Grealis K, El-Bassel N, Lounsbury D, Dsouza N, Bhuiyan J J Subst Use Addict Treat. 2024; 169:209566.

PMID: 39527983 PMC: 11769743. DOI: 10.1016/j.josat.2024.209566.


An interrupted time series analysis of fentanyl, naloxone, and opioid-involved deaths in five counties in Eastern Missouri.

Newman S, McNamara I, Campbell K, Park B, Carpenter R, Blanchard B J Subst Use Addict Treat. 2024; 169:209564.

PMID: 39505112 PMC: 11769757. DOI: 10.1016/j.josat.2024.209564.


Effectiveness of direct patient outreach with a narrative naloxone and overdose prevention video to patients prescribed long-term opioid therapy in the USA: the Naloxone Navigator randomised clinical trial.

Glanz J, Mueller S, Narwaney K, Wagner N, Xu S, Kraus C BMJ Public Health. 2024; 2(1).

PMID: 39421268 PMC: 11485839. DOI: 10.1136/bmjph-2023-000725.


References
1.
Xu J, Davis C, Cruz M, Lurie P . State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies. Drug Alcohol Depend. 2018; 189:37-41. DOI: 10.1016/j.drugalcdep.2018.04.020. View

2.
McDonald R, Campbell N, Strang J . Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-Conception and maturation. Drug Alcohol Depend. 2017; 178:176-187. DOI: 10.1016/j.drugalcdep.2017.05.001. View

3.
Graves R, Andreyeva E, Perrone J, Shofer F, Merchant R, Meisel Z . Naloxone Availability and Pharmacy Staff Knowledge of Standing Order for Naloxone in Pennsylvania Pharmacies. J Addict Med. 2018; 13(4):272-278. PMC: 6870176. DOI: 10.1097/ADM.0000000000000492. View

4.
Wu C, Brown T, Moreno J . Access to naloxone at community pharmacies under the Massachusetts statewide standing order. J Am Pharm Assoc (2003). 2019; 60(4):647-652. DOI: 10.1016/j.japh.2019.11.009. View

5.
Roberts A, Look K, Trull G, Carpenter D . Medicaid prescription limits and their implications for naloxone accessibility. Drug Alcohol Depend. 2020; 218:108355. PMC: 7568500. DOI: 10.1016/j.drugalcdep.2020.108355. View